DataMeds AI plans ChemoFx marketing relaunch, targets gynecologic cancer diagnostic rollout

DataMeds AI will cut corporate management roles to redirect spending toward commercializing the ChemoFx diagnostic for gynecologic cancers. A marketing relaunch is being prepared, targeting oncologists to drive adoption of ChemoFx for chemotherapy regimen selection. ChemoFx will be positioned for broader payer uptake following its first inclusion in a Humana Medicaid coverage policy for gynecologic cancers. Additional clinical-utility analyses are being readied for peer review to support expansion into other solid tumors. Research collaborations are being pursued using a 70,000-sample tumor repository, alongside development of an oncology module in Health Lives Here. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. DataMeds AI Inc. published the original content used to generate this news brief via (Ref. ID: 202610130600ACCESSWRNAPR_____1236187) on October 13, 2026, and is solely responsible for the information contained there